أفضل العلاج المناعي لسرطان الكلى طب الأورام - توب -51 أطباء

الدكتور يسيم يلدريم أستاذ طب الأورام في مركز الأناضول الطبي وعضو في الجمعية الأوروبية لطب الأورام (ESMO). وهي متخصصة في العلاج المناعي للسرطان والعلاجات المستهدفة وتشخيص وعلاج الأورام الخبيثة ونشرت أكثر من 80 منشورًا وملخصات وكتابًا دوليًا ووطنيًا. وهي حاصلة أيضًا على ماجستير في إدارة الأعمال في إدارة الرعاية الصحية وتتقن اللغة الإنجليزية والروسية والتركية.

مصطفى سولاك ، دكتوراه في الطب ، هو طبيب تخرج من كلية الطب بجامعة هاسيتيب وأتم إقاماته في مستشفى شيشلي إتفال التعليمي والبحوث بإسطنبول ومنح الزمالة في معهد السرطان بجامعة هاسيتيب. وهو متخصص في سرطان الثدي وسرطان الخصية وسرطان المبيض وسرطان الرئة وسرطان الرأس والعنق وسرطان الجهاز الهضمي. وقد عمل أيضًا في مركز إم دي أندرسون للسرطان بجامعة تكساس ، ومستشفى كوروم للتدريب بجامعة هيتيت ، ومستشفى ميديكال بارك.

AREAS OF INTEREST

• Breast cancer
• Colon cancer
• Lung cancer
• Malignant melanoma
• Urogenital cancers
• Gynecological cancers
• Digestive system cancers

Education and Specialization

• 1987-1993 BSc Faculty of Medicine, Uludağ University Faculty of Medicine
• 1994-1999 BSc Internal Medicine Ondokuz Mayıs University Faculty of Medicine
• 2008-2011 PhD Medical Oncology Ankara Numune Training and Research Hospital
• 2016 Assoc. Prof. / Prof. Dr. Medical Oncology Okmeydanı Training and Research Hospital

Experience

• 1993-1994 General Practitioner Senirkent State Hospital Senirkent, Isparta
• 1994-1999 Research Position Ondokuz Mayıs University Faculty of Medicine Internal Medicine Department, Samsun
• 2000-2006 Specialist Doctor Diyarbakır SSK Hospital, Diyarbakır
• 2006-2008 Specialist Doctor Diyarbakır State Hospital, Diyarbakır
• 2008-2011 Dr. Minor Assistant Ankara Numune Training and Research Hospital
• 2011-2013 Specialist Doctor Diyarbakır Training and Research Hospital, Medical Oncology
• 2013- 2016 Specialist Doctor Okmeydanı Training and Research Hospital, Medical Oncology Clinic
• 2016 Education Manager Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Assoc. Prof.

Professional Memberships

Turkish Society of Medical Oncology

Education and Training:

• Medical Degree: Graduated from Uludağ University Faculty of Medicine in 1993.
• Specialization in Internal Medicine: Completed at Ondokuz Mayıs University Faculty of Medicine in 1999.
• Medical Oncology Fellowship: Completed at Ankara Numune Research and Training Hospital in 2011.
•  
• Professional Experience:
• Isparta Senirkent State Hospital: Completed his mandatory service as an Internal Medicine Specialist and Hemodialysis Responsible Physician (1993-1994).
• Prof. Dr. Gazi Yaşargil Training and Research Hospital: Served as a Medical Oncologist (2011-2013).
• Okmeydanı Research and Training Hospital: Achieved the title of Associate Professor and later full Professor, significantly contributing to medical oncology (2013-2016).
• Current Position: Professor of Medical Oncology at İstinye University Hospital Medical Park Gaziosmanpaşa, Istanbul, where he continues to provide top-tier oncology care and mentorship.

Areas of Expertise:

• Cancer Treatment: Specializes in the treatment of various cancers, including breast, colon, lung, malignant melanoma, urogenital, gynecological, and gastrointestinal cancers.
• Advanced Therapies: Proficient in administering chemotherapy, immunotherapy, and other cutting-edge treatments for cancer patients.
• Research and Education: Actively involved in cancer research and dedicated to educating the next generation of oncologists, continuously enhancing the field through both clinical practice and academic contributions.

• Extensive Experience:
•  
• With over 24 years of medical practice, Prof. Dr. Cihan is a highly respected figure in oncology, known for his comprehensive approach to cancer treatment.
• International Recognition: Participates in numerous international seminars and congresses, keeping abreast of the latest advancements in oncology.
• Patient-Centric Care: Renowned for his compassionate and personalized approach to patient care, ensuring tailored treatment plans that address the unique needs of each patient.
• Multidisciplinary Collaboration: Works with a multidisciplinary team of experts at Medical Park, providing holistic and coordinated care to achieve the best possible outcomes for patients.

Achievements and Awards:

• Academic Contributions: Has contributed significantly to oncology literature and research, with numerous publications in reputable medical journals.
• Leadership in Oncology: Recognized for his leadership in oncology, both in clinical settings and academic institutions, influencing cancer treatment practices and policies.

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

الاختصاصي الرائد في إسرائيل في علاج الساركوما وسرطان الرئة ، رئيس المركز الوطني لساركوما العظام والأنسجة الرخوة في مركز تل أبيب الطبي في سوراسكي (إيخيلوف)

تخصص:

• علاج جميع أنواع سرطان الرئة وأعضاء الصدر
• علاج جميع أنواع أورام العظام والأنسجة الرخوة
• علاج الأورام اللحمية في الجهاز الهضمي

التعليم والتخصص:

• تعليم طبي عالي ، تخرج من كلية الطب في الجامعة العبرية في القدس ، إسرائيل
• الإقامة في علاج الأورام العامة والعلاج الإشعاعي
• تدريب في مجال العلاج الإشعاعي والمعالجة الكثبية في مستشفى نيويورك ، الولايات المتحدة الأمريكية
• دورة تنشيطية خاصة لعلاج أورام الهيكل العظمي والأنسجة الرخوة ، باريس. فرنسا

عضوية:

• رئيس جمعية أطباء الأورام والمعالجين بالأشعة إسرائيل
• جمعية السرطان العلمية الأمريكية
• المنظمة الطبية العلمية الأوروبية
• الجمعية الأوروبية لأورام الجهاز الحركي
• الجمعية الدولية لعلاج أورام النسيج الضام

الدكتور ديفيد ساريد متخصص في طب الأورام والعلاج الإشعاعي في إسرائيل ولديه خبرة في العلاج الكيميائي والعلاج الإشعاعي وعلاج السرطان البيولوجي. تلقى تعليمه في المملكة المتحدة وإسرائيل وجورجيا وكتب أكثر من 30 مقالة مخصصة لعلاج السرطان. محاضر في جامعة تل أبيب وعضو في العديد من المنظمات الطبية.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

الدكتور درور ليفين هو طبيب أطفال كبير ومدير أقسام علاج اضطرابات الدم وسرطان العظام (ساركوما) في مستشفى الأطفال "دانا" والمركز الطبي "سوراسكي" على التوالي. وهو متخصص في طب الأطفال وأمراض الدم والأورام ، ولديه خبرة إضافية في الدراسة بالخارج في معهد ريزولي لتقويم العظام في إيطاليا.

الدكتور راج هو طبيب أورام جراحي ذو خبرة عالية ولديه 19 عامًا من الخبرة وأكثر من 50000 عملية جراحية للسرطان. يشارك في العديد من التجارب السريرية وله العديد من المنشورات الدولية والوطنية لحسابه. وهو متخصص في جراحة أورام الثدي والصدر ويعمل كأستاذ في DNB للتخصصات الفائقة في جراحة الأورام وجراحة الثدي في جامعة ماهاراشترا للعلوم الصحية. إيمانه هو "إضافة الحياة إلى سنوات" وتحسين نوعية الحياة ، وليس فقط إضافة سنوات إلى الحياة.

Field of Speciality: Urology
Date of Birth: 1980
School of Medicine:  Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English

Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.

Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot

​

After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments

His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement   Penile Implants , Penile Enhancement , SafeFill and MaleShot  into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.

(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)

​

Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.

​

​

OTHER AREAS OF FOCUS

Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias

​

Membership of Scientific Organizations

Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications

• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en

​

الدكتور الراوي هو طبيب أورام جراحي مؤهل تأهيلاً عالياً وذو خبرة حاصل على شهادة البورد ولديه خبرة في علاج أورام الجهاز الهضمي العلوي والرأس والرقبة والحد الأدنى من التدخل الجراحي وأورام الثدي والقولون والمستقيم والتدفئة الكيميائية. وقد شغل مناصب في مراكز سرطان الإحالة من الدرجة الثالثة ويشغل حاليًا منصب مدير خدمات الأورام في نظام مستشفى VPS في الإمارات العربية المتحدة ومنطقة الشرق الأوسط وشمال إفريقيا. كما يشارك في أبحاث الأورام.

أخصائي طب الأورام من ذوي الخبرة مع 11 عامًا من الخبرة ، عمل في العديد من المرافق الطبية بما في ذلك كلية الطب بجامعة باموكالي ، ومستشفى هكاري الحكومي ، ومستشفى الدكتور لطفي كاردار كارتال للتدريب والبحوث ومستشفى أدرنة سلطان مراد الأول الحكومي. عضو في الجمعية التركية لطب الأورام ، والجمعية الأوروبية لطب الأورام ، والجمعية الأمريكية لعلم الأورام السريري ، وجمعية علم الأورام المناعي ، والجمعية الطبية التركية.

حصل الدكتور X على بكالوريوس في الطب من أنقرة (1976) ، وتخصص في الطب الباطني من أنقرة (1981) ، وتخصص ثانوي في طب الأورام من اسطنبول (1987). شغل مناصب مختلفة في علم الأورام والطب الباطني منذ عام 1986 ، وهو عضو مؤسس وعضو نشط في العديد من جمعيات الأورام والمنظمات العلمية مثل جمعية الأورام التركية ، وجمعية الأورام الطبية ، وجمعية العلاج الكيميائي ، والجمعية الأوروبية لطب الأورام ، والجمعية الأمريكية قسم الأورام السريرية ، والجمعية الأوروبية لأبحاث السرطان السريرية.

الدكتور X هو طبيب أورام طبي يتمتع بخبرة تزيد عن 30 عامًا. حصل على تعليم طبي من جامعة اسطنبول وتخصص في الطب الباطني وتخصص طب الأورام من معهد الأورام بجامعة اسطنبول. وهو عضو في جمعية الأورام الطبية ، وجمعية سرطان الرئة ، و ESMO ، و ASCO ، وغرفة اسطنبول الطبية.

أخصائي الأورام الطبي ذو الخبرة في سرطان الرئة والثدي والقولون والمستقيم والمعدة والكبد والكلى والبنكرياس والمعدة والبروستاتا والرحم. من ذوي الخبرة في العلاج الكيميائي ، والعلاج المناعي ، والعلاج بالنباتات ، والعلاج بالأوزون ، والعلاج الكيميائي عالي الحرارة ، وسرطان نظم المعلومات الجغرافية ، وأمراض النساء وسرطان الجهاز البولي التناسلي. عضو في مجموعة الأورام التركية ، وجمعية الأورام الطبية ، والجمعية التركية لأبحاث السرطان والحرب ، والجمعية الأوروبية لطب الأورام الطبي ، والجمعية الأوروبية لأورام أمراض النساء ، والرابطة الدولية لدراسة سرطان الرئة.